Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ENPP3 | O14638 | 3/20 | 0.52 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9852204 | 0.90 | MEN1 (0.60) | MEN1KMT2AENPP3ENPP1ENPP2 | |
| SCHEMBL4126086 | 0.90 | MEN1 (0.60) | MEN1KMT2AENPP3ENPP1ENPP2 | |
| SCHEMBL18179825 | 0.90 | MEN1 (0.60) | MEN1KMT2AENPP3ENPP1ENPP2 | |
| Iodide SCHEMBL22068772 | 0.88 | CA2 (0.59) | MEN1KMT2AENPP3ENPP1ENPP2 | |
| SCHEMBL9870770 | 0.85 | TDP1 (0.68) | MEN1KMT2AENPP3ENPP1ENPP2 | |
| SCHEMBL12584886 | 0.85 | TDP1 (0.68) | MEN1KMT2AENPP3ENPP1ENPP2 | |
| SCHEMBL4074430 | 0.85 | MEN1 (0.65) | MEN1KMT2AENPP3ENPP1ENPP2 | |
| SCHEMBL941647 | 0.85 | GAA (0.64) | MEN1KMT2AENPP3ENPP1ENPP2 | |
| SCHEMBL6937173 | 0.85 | CA2 (0.64) | MEN1KMT2AENPP3ENPP1ENPP2 | |
| SCHEMBL8069392 | 0.83 | MEN1 (0.54) | MEN1KMT2AENPP3ENPP1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7494760-B2 | Photoacid generators, chemically amplified resist compositions, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20090017112-A1 | Compounds for Inhibiting Beta-Amyloid Production | ROSKAMP RESEARCH LLC (US) | 2009-01-15 | — | — | US | disclosed |
| US-20070287096-A1 | Photoacid generators, chemically amplified resist compositions, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. | 2007-12-13 | — | — | US | disclosed |
| US-6916591-B2 | Photoacid generators, chemically amplified resist compositions, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2005-07-12 | — | — | US | disclosed |
| US-20030215738-A1 | Photoacid generators, chemically amplified resist compositions, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090017112-A1 | Compounds for Inhibiting Beta-Amyloid Production | PSEN1, PSEN2, APP | MEN1 3748/4885KMT2A 4404/4885ENPP3 1368/4885 |
| US-20030215738-A1 | Photoacid generators, chemically amplified resist compositions, and patterning process | CCNH, PAH, POLH | MEN1 4466/4885KMT2A 890/4885ENPP3 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.